Rhythm Pharmaceuticals, Inc. announced that a new International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code for Bardet-Biedl Syndrome (BBS) was approved by the Centers for Disease Control and Prevention (CDC). The new code, Q87.83 Bardet-Biedl syndrome (BBS), takes effect Oct. 1, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.97 USD | +0.73% | +12.02% | -13.05% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.05% | 2.44B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- RYTM Stock
- News Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome